Favipiravir (T-705)

製品コード：S7975 純度：99.97%

Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.

CAS No. 259793-96-9

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 29500	国内在庫あり
5mg	JPY 22000	国内在庫あり
25mg	JPY 59500	国内在庫あり
100mg	JPY 149500	国内在庫あり
1g	JPY 295500	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

文献中Selleckの製品使用例（23）

1/2

カスタマーフィードバック2例

製品安全説明書

現在のバッチを見る：純度： 99.97%

99.97

Favipiravir (T-705)関連製品

関連ターゲット	tRNA synthetase RdRp DNA synthesis helicase ribonucleotide reductase	もっと見る
関連製品	Pidnarulex (CX-5461) SCR7 RK-33 Carmofur Triapine (3-AP) B02 BMH-21 YK-4-279 Bergapten Tegafur (FT-207) Azaguanine-8 Halofuginone Adenine HCl Mizoribine Cyclocytidine HCl Thymidine APX-3330 Nedaplatin 6-Thio-dG Flupirtine maleate JH-RE-06 Pritelivir (BAY 57-1293) TK216 Amenamevir Madrasin Tubercidin BC-LI-0186 CRT0044876 PFM01 Adenine ML216	もっと見る
関連化合物ライブラリー	FDA-approved Drug Library Natural Product Library Apoptosis Compound Library DNA Damage/DNA Repair compound Library Cell Cycle compound library	もっと見る

シグナル伝達経路

DNA/RNA Synthesisシグナル伝達経路

DNA/RNA Synthesis阻害剤の選択性比較

阻害剤	Citation	tRNA synthetase	RdRp	DNA synthesis	helicase	YB-1	ribonucleotide reductase	ribonucleotide reductase	PCNA	その他
ART899	0
ART812	0
ART558	0
SU056	2					+
VV116	0		+
BC-LI-0186	1	+++
Acelarin (NUC-1031)	0			++++
Suramin sodium salt	1		++							SirT1,SirT2,Topoisomerase II
ML216	3				+
Halofuginone	11	+++								Smad3
Clevudine	1
Nedaplatin	3			✔
Triapine (3-AP)	17						✔	✔
RP-6685	0
H3B-8800	0
Basic Orange 14	0
AOH1996	0								✔
Didox	0						✔	✔
Phen-DC3 Trifluoromethanesulfonate	0				✔
Robinetin	0			✔
Metarrestin	0									PNC
Brr2 Inhibitor C9	0				✔
Triglycidyl Isocyanurate (Teroxirone)	0			✔						p53
RK-33	21				✔
Oxolinic acid	0			✔						bacterial DNA gyrase,dopamine uptake
Favipiravir (T-705)	23		✔
YK-4-279	14				✔
Blasticidin S HCl	29			✔						protein synthesis
CX-3543(Quarfloxin)	0

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
MDCK	Antiviral assay	250 uM	10 hrs	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA sytheis at 250 uM added together with virus and measured at 10 hrs post infection by RT-qPCR method, NULL = NULL μM.	29906392
MDCK	Antiviral assay	100 uM	12 hrs	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA synthesis at 100 uM preincubated with cells for 12 hrs followed by viral infection measured after 10 hrs post infection by RT-qPCR metho, NULL = NULL μM.	29906392
MDCK	Antiviral assay		2 to 5 hrs	Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 2 to 5 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM.	30192544
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.

Targets

RNA-dependent RNA polymerase ^[1]

In Vitro
In vitro	Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml. ^[1] In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis. ^[2]
細胞実験	細胞株	MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells
	濃度	1000 μg/mL
	反応時間	3 days
	実験の流れ	The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 10³ cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO₂. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).
実験結果図	Methods	Biomarkers	結果図	PMID
	Growth inhibition assay	Survival Cell viability		26711718
	IHC	H&E Staining NiV nucleoprotein LASV antigen H&E stain		29765101
	Immunofluorescence	rNiV-Gluc		29765101

In Vivo
In Vivo	In influenza virus-infected mice, Favipiravir (200 mg/kg/day, p.o.) protects the mice from death from influenza virus infection. ^[1] In mice experimentally infected with Ebola virus, Favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6days after initiation of treatment, respectively. ^[3]
動物実験	動物モデル	Mice infected with influenza virus A/PR/8/34
	投与量	200 mg/kg/day
	投与経路	p.o.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT06024421	Recruiting	Infectious Disease\|Pharmacology	Institut National de la Santé Et de la Recherche Médicale France\|FUJIFILM Toyama Chemical Co. Ltd.	April 2024	Phase 1
NCT05940545	Recruiting	CCHF	Liverpool School of Tropical Medicine	July 12 2023	Phase 1\|Phase 2
NCT04907682	Completed	Lassa Fever	Bernhard Nocht Institute for Tropical Medicine\|University of Hamburg-Eppendorf\|Alliance for International Medical Action\|Institut National de la Santé Et de la Recherche Médicale France\|University of Bordeaux\|Federal Medical Centre Owo\|Irrua Specialist Teaching Hospital	July 30 2021	Phase 2

参考
[1] Furuta Y, et al. Antimicrob Agents Chemother. 2002, 46(4), 977-981. [2] Baranovich T, et al. J Virol. 2013, 87(7), 3741-3751. [3] Madelain V, et al. Antiviral Res. 2015, 123, 70-77.

参考

化学情報

分子量	157.1	化学式	C₅H₄FN₃O₂
CAS No.	259793-96-9	SDF	Download Favipiravir (T-705) SDFをダウンロードする
Smiles	C1=C(N=C(C(=O)N1)C(=O)N)F
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	１ケ月-20°Cin solvent

In vitro
Batch:

DMSO : 31 mg/mL ( (197.32 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : 2 mg/mL

Ethanol : 2 mg/mL

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

Clear solution

5% DMSO 1 95% Corn oil

1.55mg/ml (9.87mM)

Taking the 1 mL working solution as an example, add 50 μL of 31 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

Clear solution

5%DMSO 1 40%PEG300 Click to order 2 5%Tween 80 Click to order 3 50%ddH2O

1.55mg/ml (9.87mM)

Taking the 1 mL working solution as an example, add 50 μL of 31 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):